Discontinuing Multifocal Contacts Does Not Diminish Treatment Effect in Myopia

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 21, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, Jan. 21, 2025 -- No evidence is seen for loss of treatment effect after discontinuing soft multifocal contact lenses in older teenagers with myopia, according to a study published online Jan. 16 in JAMA Ophthalmology.

David A. Berntsen, O.D., Ph.D., from the University of Houston College of Optometry, and colleagues examined whether there is a loss of treatment effect (rebound) after discontinuing soft multifocal contact lenses in the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study involving 248 children (aged 11 to 17 years at baseline) with myopia who completed the BLINK randomized clinical trial. All children in the BLINK2 study wore high-add (+2.50 diopter [D]) multifocal soft contact lenses for two years and single-vision soft contact lenses during the third year to ascertain whether rebound occurred.

The researchers found that the mean axial length and spherical equivalent refractive error were 25.2 mm and −3.40 D, respectively, at baseline. Regardless of the original BLINK treatment assignment, axial elongation increased by 0.03 mm/year after participants switched from multifocal to single-vision contact lenses, and myopia progression increased by −0.17 D per year after switching to single-vision contact lenses. Throughout BLINK2, there continued to be a difference in axial length and refractive error based on the BLINK Study treatment assignment; shorter eyes and less myopia were seen in the original high-add group than in the original medium-add (+1.50 D) and single-vision groups.

These results "support fitting children with multifocal contact lenses for myopia control at a younger age and, when possible, continuing treatment until the late teenage years when myopia progression has naturally slowed," the authors write.

Several authors disclosed ties to the ophthalmic industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-22 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords